| Nov 21 |
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
|
| Nov 18 |
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
|
| Nov 14 |
Humacyte prices 2.8M shares at $5.34 in registered direct offering
|
| Nov 14 |
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
|
| Nov 10 |
Humacyte, Inc. (HUMA) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Humacyte rises 6% as regulators reviewing bioengineered human tissue asset
|
| Nov 8 |
Humacyte GAAP EPS of -$0.33 misses by $0.08
|
| Nov 8 |
Humacyte Third Quarter 2024 Financial Results and Business Update
|
| Nov 7 |
Humacyte Q3 2024 Earnings Preview
|
| Nov 6 |
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
|
